glibenclamide / Generic mfg. - LARVOL DELTA

Midchildhood Obesity After Exposure to Gestational Diabetes Mellitus: The SWIFT Study in Youth. (PubMed, Diabetes Care) - "Children exposed to GDM diagnosed before the standard time frame of 24 weeks, regardless of treatment type, meeting of glycemic targets, or maternal prepregnancy BMI, are more likely to develop obesity up to 11 years later."

Journal • Diabetes • Genetic Disorders • Gestational Diabetes • Metabolic Disorders • Obesity

Systematic review and synthesis without meta-analysis (SWiM) reveals lack of clinical studies and weak preclinical evidence for interaction between glucose regulating drugs and environmental contaminant exposure. (PubMed, Biochem Pharmacol) - "Exendin-4 was investigated twice and glibenclamide once. Small sample sizes, short duration exposures, unrealistic chemical levels, lack of full factorial analysis and absence of testing in suitable T2D models restrict the applicability of the current, limited preclinical evidence for translation to clinical practice. The potential for chemical exposure to impact T2D medication effects on glucose control needs to be addressed with dedicated clinical studies in patients with T2D."

Journal • Preclinical • Retrospective data • Metabolic Disorders

Properties of AgNPs stabilized with polyvinylpyrrolidone relevant to antidiabetic agents. (PubMed, Nanoscale) - "In vivo studies showed that AgNPs inhibited α-amylase, α-glucosidase, and dipeptidyl peptidase-4, up to 3.51, 3827.76, and 11 times more effective than acarbose and sitagliptin, respectively. Advanced glycation end products inhibition by AgNPs was up to 61.4 times higher than metformin. In vivo experiments revealed that AgNPs antihyperglycemic activities were close to acarbose, while the same hypoglycemic effect was achieved with AgNP doses up to 167 times lower than that of glibenclamide. The results show the possibility to decrease the glibenclamide dose by two orders, that indicates high AgNP perspective to reduce drug toxicity and side effects."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Exploring natural AMPK activators from bioactive compounds in fenugreek and oyster mushroom for management of type 2 diabetes. (PubMed, Sci Rep) - "Molecular dynamics simulations further demonstrated that the selected ligands formed more stable ligand-protein complexes with fewer fluctuations compared to the control drug, glibenclamide. Overall, this study suggests that 2',6'-Dihydroxyacetophenone, 1-Methyl-2-phenylbenzimidazole, and N-Methylphthalimide are potential AMPK direct activators capable of mitigating Type 2 diabetes through an insulin-independent pathway. However, further in vitro and in vivo validation is required."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Navigating complementary and alternative medicine use, medication adherence, and herb-drug interaction risks among gout patients: a multicenter cross-sectional study in indonesia. (PubMed, J Complement Integr Med) - "The frequent use of CAM among gout patients highlights the crucial role of healthcare practitioners in educating patients about safety, efficacy, and potential interactions. It also underscores the need for strategies to address medication non-adherence associated with CAM use and to monitor herb-drug interactions in clinical settings."

Journal • Observational data • Gout • Inflammatory Arthritis • Rheumatology

Effects of nicorandil on inflammatory response, oxidative stress and myocardial fibrosis after myocardial infarction. (PubMed, BMC Cardiovasc Disord) - "Nicorandil attenuates myocardial inflammation, oxidative stress and myocardial fibrosis levels by activating ATP-sensitive potassium channels (K-ATP), thereby improving post-MI cardiac remodeling and preserving cardiac function."

Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • Myocardial Infarction • IL1B • IL6 • TNFA

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of the antidiabetic potential of Acmella Oleracea (L): selection of optimal plant part and solvent extract via in vitro assays and their validation in alloxan-induced mice model. (PubMed, 3 Biotech) - "All tested doses markedly reduced blood glucose levels (p < 0.001) compared to the diabetic control, with the 300 mg/kg dose producing the greatest reduction (51.37%) and efficacy comparable to glibenclamide (~ 0.94-fold)...However, further studies are required to validate these effects in other diabetic models. The online version contains supplementary material available at 10.1007/s13205-025-04588-9."

Journal • Preclinical • Diabetes

Pharmacological risks of khat-oral antidiabetic drug interactions among patients at Gondar university referral hospital. (PubMed, Sci Rep) - "Harmful khat-OAD interactions are common among T2DM patients in Northwest Ethiopia, primarily driven by behavioral and treatment-related factors, highlighting the need for culturally sensitive pharmacovigilance and patient education."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Noninsulin drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Assessment of intranasal permeability and pharmacological activity of glyburide-loaded nanosuspension formulation for Alzheimer's disease. (PubMed, J Pharm Sci) - "In vivo behavioural tests demonstrated that the nanosuspension formulation yielded favourable and promising outcomes even it was administered intranasally. This study suggests that, through the solubility enhancement provided by nanocrystal technology increased the bioavailability of glyburide comparing the intranasal administration of glyburide, leading to improve in vivo activity compared to the raw glyburide suspension in the treatment of Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders

SUR1-TRPM4 is expressed in human epilepsy and promotes neuron hyperactivity and seizures in rodents. (PubMed, Brain) - "Pharmacologic inhibition of SUR1-TRPM4 using either the FDA-approved drug glyburide or 9-phenanthrol, as well as either constitutive or neuron-specific knock-out of this channel, attenuated chronic seizure development in this model...Collectively, our results reveal that elevated SUR1-TRPM4 expression found in human and rodent epileptic neurons promotes chronic seizures by increasing neuronal excitation. These findings directly support clinical investigation of SUR1-TRPM4 inhibitors as potential anti-seizure therapies in epilepsy patients and suggest further investigations into the contribution of SUR1-TRPM4 to seizures induced by specific epileptogenic insults, such as TBI, are warranted."

Journal • Preclinical • Cardiovascular • CNS Disorders • Epilepsy • Vascular Neurology

Antioxidant and antidiabetic effects of Angylocalyx oligophyllus leaves aqueous extract in pregnant diabetic rats: Feto-maternal repercussions. (PubMed, PLoS One) - "The pregnant rats were distributed into normal and diabetic control groups receiving distilled water, and diabetic rats groups treated with the plant extract doses (50, 100 and 200 mg/kg) or Glibenclamide (standard; 10 mg/kg)...In pregnant diabetic rats, the plant significantly (p < 0.5-p < 0.001) reduced the serum levels of glucose, total cholesterol, triglycerides, LDL-cholesterol, transaminases liver MDA, SOD, CAT and GSH, and post-implantation losses, increased the serum HDL-cholesterol and 17-β-estradiol, the number of pancreatic cells, implantation sites and live fetuses, while reducing placental and caudal malformations, and normalizing fetal weights in offsprings. The A. oligophyllus supplementation during pregnancy would be beneficial in preventing reproductive complications related to diabetes mellitus."

Journal • Preclinical • CNS Disorders • Developmental Disorders • Diabetes • Gestational Diabetes • Metabolic Disorders • Psychiatry

Halting of Progression of CKD Stage 5 with Finerenone (KIDNEY WEEK 2025) - "Introduction Finerenone is a non-steroidal aldosterone receptor antagonist, FDA approved to slow progression of diabetic nephropathy Case Description A 76 year old male with CKD V, eGFR of 13 in November 2021 began treatment for diabetes with Glyburide, Losartan and Finerenone. Discussion This report represents an extraordinary slowing of progression of CKD V. In the study of KU et al, (Clin J Amer Soc May 2018 Neph) the median time for patients with CKD V remaining free of dialysis was 9.6 months. Finerenone appears to be responsible for the halting of progression of CKD V in this patient."

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease

Metformin-Associated Lactic Acidosis Triggered by Combined Use of Metformin and a GLP-1 Receptor Agonist: A Report of Two Cases (KIDNEY WEEK 2025) - "The second patient is a 69-year-old woman who presented with nausea, vomiting, and diarrhea 2 weeks after a semaglutide dose increase, while on metformin, lisinopril, linagliptin, and glyburide. We propose possible side-effect synergism when metformin and a GLP-1 RA are co-prescribed, with a heightened risk of renal dysfunction and unintentional metformin toxicity, specifically MALA. Prudence should be exercised when co-prescribing these 2 classes with close monitoring of kidney function and possibly reducing the dose of metformin, and there should be emphasis on sick day rule teaching."

Clinical • Acute Kidney Injury • Anorexia • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Kaempferol Promotes Vasorelaxation via KV2.1 Channel Modulation in the Coronary Arteries of Sheep. (PubMed, Planta Med) - "Inhibition of nitric oxide synthase (NOS) with L-NAME (100 μM) and cyclooxygenase (COX) with indomethacin (10 µM) did not significantly alter the relaxation response, suggesting that nitric oxide (NO) and prostaglandins play a minimal role. The BKCa channel blocker TEA (1 mM), ATP-sensitive potassium (KATP) channel blocker glibenclamide (10 µM), and inward-rectifier potassium (KIR) channel blocker BaCl2 (30 μM) did not significantly affect kaempferol-induced relaxation. However, inhibition with the voltage-gated potassium (KV) channel blocker 4-aminopyridine (3 mM) significantly reduced the relaxation response indicating the involvement of KV channels...These findings suggest that kaempferol promotes vasorelaxation through an endothelium-independent mechanism, with partial involvement of KV2.1 channel. This study supports kaempferol's therapeutic potential in cardiovascular disease, recommending its dietary inclusion as a strategy to lower the risk of..."

Journal • Cardiovascular

Vasorelaxant effects of the edible flowers Tagetes erecta L. and its possible mechanism of action. (PubMed, Pharm Biol) - "Vasorelaxant effect was attenuated by endothelial removal and by pretreatment with L-NAME or ODQ, but not by indomethacin...Relaxation was significantly attenuated by iberiotoxin, glibenclamide, BaCl2, and 4-aminopyridine, while apamin and TRAM-34 had mild effect...At low concentrations, relaxation was mediated by nitric oxide, while at higher concentrations it involved inhibition of intracellular Ca2+, opening of K+ channels, and activation of protein kinase A. In C. elegans, the extracts significantly reduced pharyngeal pumping. This study is the first to suggest that T. erecta could be beneficial in treating pathologies associated with endothelial dysfunction, such as hypertension."

Journal • Cardiovascular • Hypertension

Intracellular Calcium Changes Correlate with Mitochondrial Dynamics After Differential Modulation of KATP Channels in a Cellular Model of Parkinson's Disease. (PubMed, Neurochem Res) - "SH‑SY5Y cells with its high fidelity to dopaminergic neurons were treated for 24 h with the non‑selective KATP opener pinacidil and blocker glibenclamide, or with the mitochondrial KATP opener diazoxide and blocker 5‑hydroxydecanoate (5HD)...More distinctive results were obtained for agonists: both reduced calcium concentration; however, pinacidil tended to induce mitochondrial fragmentation, an effect absent in diazoxide-treated cells. Furthermore, strong correlations were identified between calcium levels and several mitochondrial and cell viability parameters."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

DM4PHC-pilot: Diabetes Management for Primary Healthcare Centers. (clinicaltrials.gov) - P=N/A | N=106 | Recruiting | Sponsor: University of Abuja | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2026 ➔ Dec 2026 | Initiation date: Apr 2025 ➔ Sep 2025

Enrollment open • Trial completion date • Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: University of Maryland, Baltimore

New P1 trial • CNS Disorders • Multiple Sclerosis • Neuralgia • Pain

Antiseizure Effects of Mirtazapine in a Rat Model of Status Epilepticus Via Cannabinoid Receptor Modulation. (PubMed, Neurochem Res) - "Diazepam (1 mg/kg), a GABAA positive allosteric modulator, was co-administered with mirtazapine to assess potential involvement of GABA receptors in mirtazapine's effects. The effects of KATP channel modulation were studied using glibenclamide (3 mg/kg), a KATP channel blocker...This study shows that only pre-treatment with mirtazapine can effectively prevent SE primarily through the activation of CB1 and CB2 cannabinoid receptors. Further studies, including clinical trials, are needed to validate these findings."

Journal • Preclinical • CNS Disorders • Epilepsy • IDO1

The Analytical Evolution of Glibenclamide (Glyburide) Antidiabetic Agents: Analytical Tools, Challenges, and Future Trends. (PubMed, Crit Rev Anal Chem) - "Finally, this review identifies key future directions, emphasizing the integration of green analytical chemistry principles, miniaturized platforms, and nanostructured sensing technologies to advance selective, sensitive, and environmentally sustainable glyburide analysis. These innovations hold the potential to transform glyburide monitoring from laboratory-based methods to real-world applications, including point-of-care testing and environmental health monitoring."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Phytochemical Composition and Acute Hypoglycemic Effect of Jefea lantanifolia (S. Schauer) Strother in Rats. (PubMed, Plants (Basel)) - "In vivo experiments showed significant reductions in blood glucose levels during fasting, with compounds 2 and 3 achieving reductions of 42% and 40%, respectively, compared to 51% with glibenclamide...These findings support the traditional use of J. lantanifolia and highlight its phytochemicals as promising candidates for further pharmacological investigation. Long-term studies and high-dose evaluations are warranted to validate therapeutic potential and establish safety profiles."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Muscle fatigue arising intrinsically from SUR2- but not Kir6.1-dependent gain-of-function in Cantu syndrome mice. (PubMed, J Gen Physiol) - "Importantly, normal contractile behavior was restored ex vivo and in vivo in SUR2[A478V] muscles in the presence of the FDA-approved KATP channel inhibitor glibenclamide, indicating that the increased fatigue of isolated muscles is a direct consequence of overactive sarcolemmal KATP channels. These results shed light on the pathophysiologic relevance of SUR2-dependent KATP channel subunits in skeletal muscle and highlight their role in fatiguing conditions, as well as identifying potential therapeutic benefit of skeletal muscle KATP inhibition in CS."

Journal • Preclinical • Fatigue • Rare Diseases • MED23

Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress. (PubMed, Curr Issues Mol Biol) - "Promising results have been achieved through dual therapies that combine antioxidants (such as sesame oil, naringin, alpha-lipoic acid, resveratrol, and quercetin) with sulfonylureas (including glipizide, glibenclamide, gliclazide, and glimepiride). These recent advancements in synthetic sulfonamide research point to a promising future in diabetes management, especially considering the dual functionalities demonstrated by in vivo studies-specifically, their antidiabetic and antioxidant effects. Moreover, the synergy between sulfonamides and other antioxidant agents represents a beneficial strategy for optimizing future chemical structures, potentially allowing for their integration into personalized treatments aimed at combating T2DM."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus